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Summary We have studied the expression of p53 in 206 patients with gastric adenocarcinomas. A standard
immunohistochemical technique employing the CM-1 anti-p53 polyclonal antibody was applied to the
routinely fixed and paraffin-embedded material from these tumours; overexpression of p53 was defined as
positive nuclear staining: 46% (94/206) of gastric carcinomas expressed high levels of p53. There was no
significant correlation between p53 positivity and the tumour grade, growth pattern, the Lauren type or lymph
node metastases. Correlation with disease stage was only marginally significant (P = 0.05). Life table analysis
revealed a highly significant association between p53 expression and survival (P = 0.0062), the odds ratio of
death being 1.89 (95% confidence interval 1.33-2.69). The overall 5-year survival of patients with p53-positive
tumours was 3% compared with 16% for those with p53-negative tumours (median survival time being 5.6
and 11.4 months respectively). These data suggest that overexpression of the p53 oncoprotein is an indepen-
dent marker of shortened survival in gastric cancer patients.
p53 is a nuclear phosphoprotein first discovered as a result of
its binding to large T antigen, the dominant transforming
oncogene of the DNA tumour virus SV40 (Lane & Craw-
ford, 1979). Wild-type p53 protein is believed to be involved
in the regulation of cellular proliferation, acting by inhibition
of progression from the GI to the S-phase of the cell cycle
(Levine et al., 1991).
The human p53 gene maps to the short arm of chromo-
some 17 (Isobe et al., 1986) and is frequently mutated in a
wide variety of human cancers (Nigro et al., 1989; Lane &
Benchimol, 1990; Bartek et al., 1991; Hollstein et al., 1991).
These mutations (mostly missense) are clustered in the highly
conserved regions of the p53 genome (Nigro et al., 1989;
Hollstein et al., 1991; Varley et al., 1991) and, in addition,
there is often accompanying loss of heterozygosity at l7pl3.1
(Nigro et al., 1989; Sano et al., 1991; Varley et al., 1991).
Causal involvement of p53 abnormalities in many cancers is
indicated by the high predisposition for the development of
cancer of various types in transgenic mice with homozygous
null mutations of the gene (Donehower et al., 1992), as well
as in patients with germline mutations (Malkin et al., 1990).
Transfection of wild-type p53 into cultured malignant cells
has been shown to result in the inhibition of cellular pro-
liferation as well as morphological transformation (Finlay et
al., 1989; Mercer et al., 1990). Mutant p53 proteins may
contribute to the malignant transformation not only by the
inactivation of this suppressor activity but also by acting, in
their own right, as dominant transforming oncogenes (Jen-
kins et al., 1985; Hinds et al., 1989).
As a consequence of its short half-life, wild-type p53 is
present in cells in minute amounts and does not accumulate
to detectable levels (Gannon et al., 1990; Reihsaus et al.,
1990). In contrast, mutations are associated with a prolonga-
tion of the protein half-life; the mutant p53 gene products are
more stable and accumulate to levels that can be detected by
an immunohistochemical technique (Gannon et al., 1990;
Lane & Benchimol, 1990). Antibodies specific for human p53
have been generated (Banks et al., 1986; Gannon et al., 1990;
Bartek et al., 1991; Midgley et al., 1992; Vojtesek et al.,
1992), and the findings of a large number of immunohisto-
chemical studies have confirmed p53 accumulation to be a
very common feature of human malignancy (Bartek et al.,
1991; Scott et al., 1991; McLaren et al., 1992; Thor et al.,
Correspondence: B.V. Joypaul.
Received 8 September 1993; and in revised form 7 January 1994.
1992). Furthermore, detection of high cellular levels of p53
has been shown to correlate in most, but not all, cases with
mutation of the gene (Bartek et al., 1990; Iggo et al., 1990;
Rodrigues et al., 1990; Tamura et al., 1991).
In breast cancer (Thor et al., 1992), p53 overexpression has
been shown to be of prognostic significance. However, in
lung cancer, there is no such positive correlation (McLaren et
al., 1992). Studies in colorectal cancer have so far produced
conflicting results: some (Sun et al., 1992) link p53 overex-
pression with survival, whereas others (Scott et al., 1991) did
not find any statistical correlation between high cellular levels
of p53 and survival.
Gastric cancer is one of the most common malignancies
and carries a poor prognosis (Breaux et al., 1990). Despite
the decline in its incidence, the disease is still responsible for
about 11,000 deaths per annum in the United Kingdom
(Cancer Research Campaign, 1990). The molecular events
leading to the development of gastric cancer are largely
unknown, but there is now enough evidence to suggest that
the functional inactivation of the p53 gene through allelic
loss and mutation plays an important part (Kim et al., 1991;
Sano et al., 1991; Tamura et al., 1991; Matozaki et al.,
1992).
The aim of the present study was to determine whether
p53 status in gastric cancer is correlated statistically with
various histopathological indicators of poor prognosis and
long-term survival. We have used the polyclonal antibody
CM-1 in an immunohistochemical assay for p53 in formalin-
fixed, paraffin-embedded archival tissues from 206 patients
with primary gastric adenocarcinomas.
Materials and methods
Patientpopulation
A total of 206 patients (93 males, 113 females; mean age 67
years, ranging from 38 to 83 years) with primary gastric
adenocarcinomas diagnosed in Tayside between 1984 and
1987 were studied. All patients had undergone surgery for
the primary disease and none had received preoperative or
post-operative adjuvant therapy (radiotherapy or
chemotherapy). The tumour histology was reviewed
independently by one of us (D.H.) and the lesions were
classified in relation to the growth pattern (Ming, 1977),
nuclear grading (Watanabe et al., 1990), histologic type
(Lauren, 1965), disease stage (Miwa, 1984) and lymphatic
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Table I Analysis of p53 expression and histopathological variables
Histopathological Number Number pS3
variable of patients positive (%)
Ming type
Expansile 100 48 (48%) NS
Infiltrative 106 46 (43%)
Lauren classification
Intestinal 108 52 (48%)
Solid 42 19 (45%) NS
Diffuse 26 12 (46%)
Unclassified 30 11 (36%)
Nuclear grade
Well differentiated 7 3 (43%)
Moderately differentiated 91 42 (46%) NS
Poorly differentiated 108 49 (45%)
Tumour staging
Stage I 10 3 (30%)
Stage II 30 11 (37%) P =0.05
Stage III 73 31 (42%)
Stage IV 93 49 (53%)
Lymph node metastasesa
Positive 128 62 (48%) NS
Negative 52 20 (39%)
aData available on only 180 cases. NS, non-significant.
invasion (Table I). Representative formalin-fixed, paraffin-
embedded tissue blocks from each tumour were then used for
the immunohistochemical assay for p53.
Statistical analysis
Survival data were available for 160 patients. Life table
analysis was performed using the SPSS-PC statistical
package, which was also used to compare survival between
subgroups using the Lee-Desu statistic (Lee, 1980). To
assess the effects of risk factors while allowing for the
presence of other influences on survival, a proportional
hazards model (Cox, 1972) was fitted using the Nanostat
program, which was also used for plotting the unadjusted
survival curves.
Immunohistology
Four tissue blocks were examined from each patient. Four
micron paraffin sections were cut, mounted and air dried
overnight at 37°C. The sections were then stained for p53
using the indirect immunoperoxidase technique described
previously (Joypaul et al., 1993a). The antibody used was
CM-1, a rabbit polyclonal antiserum raised against recom-
binant human p53 protein (Midgley et al., 1992). Briefly,
CM-1 was applied at a dilution of 1:500 after blocking with
2% goat serum. Endogenous peroxidase was then blocked
using 3% hydrogen peroxide. Biotinylated anti-rabbit
immunoglobin antiserum was then applied at 1:25 dilution
followed by horseradish peroxidase-labelled steptavidin
(StrAviGen Immunodetection System, BioGenex Labs, UK).
The reaction was developed using diaminobenzidine as the
chromogen and the sections were then counterstained in light
haematoxylin.
We used Tris-buffered saline (TBS), instead of the primary
antibody, as negative controls in each case, and the positive
control sections were from a breast adenocarcinoma known
to express high levels of p53.
The sections were then assessed independently by two
pathologists (D.H. and S.Q.) without knowledge of the
clinical outcome of the patients; nuclear staining of cells was
considered positive for abnormal p53 expression.
Results
Positive p53 staining was observed in 94 of the 206 tumours
examined (46%). In no case studied was there staining of the
normal gastric epithelial cells or of stromal cells. The staining
was nuclear in all instances (Figures 1 and 2) with back-
ground or cytoplasmic staining being absent or minimal. In
the majority of the p53-positive tumours (> 70%), a diffuse
staining pattern in which all or nearly all of the cancer cells
exhibited nuclear positivity was observed (Figure 1). In con-
trast to this homogeneous pattern, the nuclear staining in the
remaining positive tumours was more varied. Here, as shown
in Figure 2, only a fraction (less than 25%) of the carcinoma
cells contained immunoreactive p53 protein.
Table I summarises the histological classification and stag-
ing of the 206 gastric adenocarcinomas studied. The numbers
of patients in each group together with the corresponding
immunohistochemical results for p53 expression are also
shown. Our findings indicate that there was no significant
association between p53 nuclear positivity and the tumour
growth pattern (expansile or infiltrative) or the histological
type (Lauren classification). Similarly, no relationship was
found between p53 expression and the nuclear grade of the
tumours. As shown in Table I, 128 of the gastric cancers had
metastasised to the perigastric lymph nodes; 52 had not and
there were no data available for the remaining 26 cases.
There was no significant relationship between p53 positivity
and nodal status (48% versus 39% respectively for the cases
with and without lymph node metastases).
Of the 206 gastric adenocarcinomas, ten were confined to
the mucosa (stage I), 30 reached the submucosa (stage II), 73
involved the muscularis propria (stage III) and the remainder
(n = 93) reached the serosa (stage IV). Our results show a
trend towards an increase in p53 expression with increasing
Figure 1 Poorly differentiated gastric adenocarcinoma immuno-
stained for p53 showing a prominent nuclear reaction. Staining is
diffuse throughout the tumour.
Figure 2 A case of gastric adenocarcinoma in which the
immunoreactivity for p53 is still nuclear but limited to a few
malignant cells only.p53 AND GASTRIC CANCER 945
depth of tumour penetration (Table I); this was found to be
marginally significant (P = 0.05).
Follow-up data were available for 160 of the 206 patients
(the prevalence of p53 positivity was 43%, not significantly
different from the total group) and, using the method of
Kaplan and Meier (Kaplan & Meier, 1958), survival curves
were plotted by p53 status (Figure 3). Analysis based on the
Cox's proportional hazards model (Cox, 1972) revealed a
significantly shortened survival time (P = 0.0062) in the p53-
positive cohort (n = 69) compared with the p53-negative
group (n = 91). The odds ratio of death, after allowing for
the effects of the other histopathological parameters in this
multifactorial analysis, was 1.89 (95% confidence interval
1.33-2.69). The effects of p53 expression on survival was not
dependent on tumour staging. Also, no difference in survival
was detected between the group of patients with homo-
geneous p53 staining and those with a heterogeneous pat-
tern.
The median survival time of the patients with and without
p53 expression was 5.6 and 11.4 months respectively (Figure
3). The overall 5-year survival for the p53 negative group was
16% compared with 3% in the p53-positive group, thus
confirming that in gastric cancer patients p53 expression is
associated with a poor prognosis.
Discussion
The placement of oncogenes in the aetiology of human
malignancy has resulted in the evaluation of an increasing
number of molecular markers as useful diagnostic or prog-
nostic indicators. p53 is the most widely studied marker and
we have previously reported that its overexpression occurs as
a late event in the gastric carcinogenic pathway (Joypaul et
al., 1993a), suggesting that p53 mutation is an important step
in the pathogenesis of gastric cancer. In the present report,
we have extended the study population to 206 patients with
primary gastric adenocarcinomas in order to determine the
association between p53 overexpression and long-term sur-
vival.
We detected increased expression of the p53 protein in
46% of the gastric tumours, and this compares favourably
with the results of a smaller study on gastric cancer (Martin
et al., 1992). In addition, the data are consistent with the
findings in other malignancies (Nigro et al., 1989; Bartek et
al., 1991; Scott et al., 1991; McLaren et al., 1992; Thor et al.,
1992). In the majority of the positive carcinomas, staining of
the p53 protein was intense and confined to all or nearly all
of the tumour cells (Figure 1). In contrast, in the remaining
positive cases, p53 staining was still nuclear but limited to a
variable fraction of the malignant cells (usually fewer than
25%, as illustrated in Figure 2). Although this heterogeneity
in staining has been attributed to causes such as the specific
type of p53 mutation (Varley et al., 1991) or cell cycle
variation in p53 levels (Morkve & Laerum, 1991; Purdie et
al., 1991; Varley et al., 1991) there is no doubt that it
represents abnormal p53 expression. It is also important to
note that this heterogeneity in staining may lead to problems
of sampling, and in this context the recently described
methods to detect p53 in homogenised tumour samples may
prove to be a useful alternative (Joypaul et al., 1993b).
In the present study, comparison of p53 nuclear staining
with various markers of high malignant potential (tumour
grade, lymph node metastases and depth of tumour penetra-
tion) did not identify any significant correlation. In contrast,









U) 0.20 p53 +ve-'1
0.0%)6 12 18 24 30 36 42 48 54 60 66 72 78 84 90
Survival (months)
Figure 3 Kaplan-Meier survival curves for p53 oncoprotein
expression in gastric adenocarcinomas.
expression to be an independent marker of shortened survival
time (P = 0.0062). This association is particularly informative
since our study population was not biased by different treat-
ment protocols as none of the patients received adjuvant
therapy (chemotherapy and/or radiotherapy). To our
knowledge, only one small study of 75 patients with gastric
cancers has examined p53 expression in relation to survival,
and the results are similar to ours (Martin et al., 1992).
Furthermore, correlation between accumulation of p53 and
survival has been reported in breast cancer (Thor et al.,
1992). Studies in colorectal and lung cancers have, however,
produced conflicting data (Scott et al., 1991; McLaren et al.,
1992; Sun et al., 1992). The cause of this possibly tissue-
specific variation is at present unknown. While the use ofp53
as a prognostic marker in gastric cancer would appear to be
justified, it is also important to consider the molecular basis
of its accumulation and its possible role as a target of novel
therapeutic agents. Until recently, molecular studies have
confirmed point mutations in the gene to be the most usual
cause of p53 accumulation (Bartek et al., 1990; Iggo et al.,
1990; Rodrigues et al., 1990; Tamura et al., 1991), but there
is now increasing evidence to suggest that other events can
also result in overexpression of the protein. These include
changes in the cellular environment resulting from DNA-
damaging events (Hall et al., 1992) or as part of the normal
apoptotic pathway (programmed cell death) (Lane, 1993). In
addition to its general correlation with expression of mutant
p53, high levels of p53 have also been linked with an increase
in cellular proliferation (Scott et al., 1991). Deficiency of
wild-type p53 could conceivably lead to a more aggressive
phenotype as a result of an excessive number of cells being
non-quiescent. Agents which could convert mutant p53 pro-
tein into a more 'wild type' conformation might therefore be
expected to inhibit proliferation and possibly induce apop-
tosis in cells with a p53-positive phenotype (Hupp et al.,
1993).
In conclusion, our study has demonstrated immunodetec-
tion of p53 in 46% of gastric adenocarcinomas, associated
with a significantly shortened survival. The hope therefore
remains that novel therapeutic agents that can target abnor-
mal or mutant p53 (thus nullifying its growth-promoting
effects) will be developed and become available in the near
future (Hupp et al., 1993).
We thank Stewart McPherson and George Coghill for the excellent
technical assistance given.
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